2025-04-08 18:29:14
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Gland Pharma Ltd posts Q4FY21 consolidated PAT up at Rs. 260.40 crore
Posted On : 2021-05-17 16:54:53( TIMEZONE : IST )
7Seas Technologies Ltd has reported financial results for the period ended March 31, 2021.
Financial Results (Q4 FY20-21) - QoQ Comparison
The company has reported total income of Rs.934.96 crores during the period ended March 31, 2021 as compared to Rs.894.54 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.260.40 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.204.10 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.15.88 for the period ended March 31, 2021 as compared to Rs.12.82 for the period ended December 31, 2020.
| Financials | Q4 FY20-21 | Q3 FY20-21 | % Change |
| Total Income | ₹ 934.96 crs | ₹ 894.54 crs |  4.52% |
| Net Profit | ₹ 260.40 crs | ₹ 204.10 crs | 27.58% |
| EPS | ₹ 15.88 | ₹ 12.82 | 23.87% |
Financial Results (Q4 FY20-21) - YoY Comparison
The company has reported total income of Rs.934.96 crores during the period ended March 31, 2021 as compared to Rs.681.43 crores during the period ended March 31, 2020.
The company has posted net profit / (loss) of Rs.260.40 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.194.79 crores for the period ended March 31, 2020.
The company has reported EPS of Rs.15.88 for the period ended March 31, 2021 as compared to Rs.12.57 for the period ended March 31, 2020.
| Financials | Q4 FY20-21 | Q4 FY19-20 | % Change |
| Total Income | ₹ 934.96 crs | ₹ 681.43 crs | 37.21% |
| Net Profit | ₹ 260.40 crs | ₹ 194.79 crs | 33.68% |
| EPS | ₹ 15.88 | ₹ 12.57 | 26.33% |
Financial Results (Year ended FY 20-21) - YoY Comparison
The company has reported total income of Rs.3597.65 crores during the 12 months period ended March 31, 2021 as compared to Rs.2772.40 crores during the 12 months period ended March 31, 2020.
The company has posted net profit / (loss) of Rs.996.96 crores for the 12 months period ended March 31, 2021 as against net profit / (loss) of Rs.772.85 crores for the 12 months period ended March 31, 2020.
The company has reported EPS of Rs.62.99 for the 12 months period ended March 31, 2021 as compared to Rs.49.88 for the 12 months period ended March 31, 2020.
| Financials | Year Ended FY20-21 | Year Ended FY19-20 | % Change |
| Total Income | ₹ 3597.65 crs | ₹ 2772.40 crs | 29.77% |
| Net Profit | ₹ 996.96 crs | ₹ 772.85 crs | 29% |
| EPS | ₹ 62.99 | ₹49.88 | 26.28% |
Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said "Overall the business has performed well and grew steadily during these challenging times. For the financial year 2020-21, we witnessed a revenue growth of 32% and net profit growth of 29% compared to the previous year. The Company continued to maintain a healthy margin profile with EBITDA margin at 40% and PAT margin at 28%. New product launches, volume growth in our existing portfolio, along with geographic expansion has led to strong business growth across all markets. Our new Vaccine business is expected to accelerate our long-term strategy of entering into Biosimilar space."
